Abiopharma

🔍 SVF Endurance (Cayman) Ltd (Executive)

Company: Vir Biotechnology, Inc. (VIR)

Report Date: 2025-10-22

Detailed Transactions and Holdings:

• Sold 144,266 shares of Common Stock at $6.1529 per share (Direct)
  Date: 2025-10-22 | Code: S | equity_swap_involved: 0 | shares_owned_after: 14,866,018.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 154,383 shares of Common Stock at $5.9898 per share (Direct)
  Date: 2025-10-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 14,711,635.00 | transaction_form_type: 4 | Footnotes: F1, F4, F3

Footnotes:

• F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.08 to $6.2552. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.92 to $6.177. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.